PR Newswire BiotechOriginal article
Снижение массы тела на 19,3 % к 48-й неделе -- данные исследования фазы III препарата Olatorepatide, двойного селективного агониста ГПП-1/ГИП компании Hansoh, представлены на EASD
Data ReadoutpositiveOlatorepatidePositive
AI Analysis
Summary
Hansoh Pharma presented Phase 3 data for Olatorepatide showing 19.3% body weight reduction at week 48 at the EASD annual conference. Olatorepatide is a dual selective GLP-1/GIP receptor agonist being developed for weight management.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
19.3% body weight reduction at week 48 in Phase 3 trial
Importance:7/10
Sentiment:
0.70
Phase 3 dataweight lossGLP-1/GIP agonistEASD conferenceobesity
Related Companies
Read the original article
Published by PR Newswire Biotech on October 3, 2026 4:58 PM